MNPR
Price
$77.19
Change
+$1.24 (+1.63%)
Updated
Dec 3 closing price
Capitalization
512.69M
Intraday BUY SELL Signals
XNCR
Price
$17.31
Change
+$1.32 (+8.26%)
Updated
Dec 3 closing price
Capitalization
1.18B
90 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MNPR vs XNCR

Header iconMNPR vs XNCR Comparison
Open Charts MNPR vs XNCRBanner chart's image
Monopar Therapeutics
Price$77.19
Change+$1.24 (+1.63%)
Volume$189.27K
Capitalization512.69M
Xencor
Price$17.31
Change+$1.32 (+8.26%)
Volume$528.19K
Capitalization1.18B
MNPR vs XNCR Comparison Chart in %
View a ticker or compare two or three
VS
MNPR vs. XNCR commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNPR is a StrongBuy and XNCR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (MNPR: $75.86 vs. XNCR: $15.99)
Brand notoriety: MNPR and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNPR: 91% vs. XNCR: 20%
Market capitalization -- MNPR: $512.69M vs. XNCR: $1.24B
MNPR [@Biotechnology] is valued at $512.69M. XNCR’s [@Biotechnology] market capitalization is $1.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNPR’s FA Score shows that 1 FA rating(s) are green whileXNCR’s FA Score has 1 green FA rating(s).

  • MNPR’s FA Score: 1 green, 4 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, MNPR is a better buy in the long-term than XNCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNPR’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 5 bullish TA indicator(s).

  • MNPR’s TA Score: 4 bullish, 4 bearish.
  • XNCR’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XNCR is a better buy in the short-term than MNPR.

Price Growth

MNPR (@Biotechnology) experienced а -14.25% price change this week, while XNCR (@Biotechnology) price change was -7.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

XNCR is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XNCR($1.18B) has a higher market cap than MNPR($513M). MNPR YTD gains are higher at: 244.818 vs. XNCR (-30.418). MNPR has higher annual earnings (EBITDA): -19.11M vs. XNCR (-125.38M). XNCR has more cash in the bank: 444M vs. MNPR (53.3M). MNPR has less debt than XNCR: MNPR (80.4K) vs XNCR (67.9M). XNCR has higher revenues than MNPR: XNCR (147M) vs MNPR (0).
MNPRXNCRMNPR / XNCR
Capitalization513M1.18B43%
EBITDA-19.11M-125.38M15%
Gain YTD244.818-30.418-805%
P/E RatioN/AN/A-
Revenue0147M-
Total Cash53.3M444M12%
Total Debt80.4K67.9M0%
FUNDAMENTALS RATINGS
MNPR vs XNCR: Fundamental Ratings
MNPR
XNCR
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
86
Overvalued
PROFIT vs RISK RATING
1..100
38100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
3436
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNPR's Valuation (30) in the null industry is somewhat better than the same rating for XNCR (86) in the Biotechnology industry. This means that MNPR’s stock grew somewhat faster than XNCR’s over the last 12 months.

MNPR's Profit vs Risk Rating (38) in the null industry is somewhat better than the same rating for XNCR (100) in the Biotechnology industry. This means that MNPR’s stock grew somewhat faster than XNCR’s over the last 12 months.

XNCR's SMR Rating (96) in the Biotechnology industry is in the same range as MNPR (97) in the null industry. This means that XNCR’s stock grew similarly to MNPR’s over the last 12 months.

MNPR's Price Growth Rating (34) in the null industry is in the same range as XNCR (36) in the Biotechnology industry. This means that MNPR’s stock grew similarly to XNCR’s over the last 12 months.

XNCR's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for MNPR (100) in the null industry. This means that XNCR’s stock grew significantly faster than MNPR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNPRXNCR
RSI
ODDS (%)
N/A
Bearish Trend 7 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 7 days ago
74%
Momentum
ODDS (%)
Bearish Trend 7 days ago
85%
Bullish Trend 7 days ago
73%
MACD
ODDS (%)
Bullish Trend 7 days ago
75%
Bullish Trend 7 days ago
67%
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 7 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
81%
Bullish Trend 7 days ago
72%
Advances
ODDS (%)
Bullish Trend 11 days ago
83%
Bullish Trend 9 days ago
72%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
Bearish Trend 15 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 7 days ago
73%
Aroon
ODDS (%)
Bullish Trend 7 days ago
74%
Bullish Trend 7 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
MNPR
Daily Signal:
Gain/Loss:
XNCR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGINX11.32N/A
N/A
DWS Global Macro Inst
LHCVX23.45N/A
N/A
Lord Abbett Health Care R6
JHLVX57.50N/A
N/A
JHancock Fundamental Large Cap Core C
CMVIX29.80N/A
N/A
BlackRock Advantage Large Cap Gr Instl
RSCRX27.35N/A
N/A
Russell Inv US Small Cap Equity R6

MNPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNPR has been loosely correlated with QNCX. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if MNPR jumps, then QNCX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNPR
1D Price
Change %
MNPR100%
-8.67%
QNCX - MNPR
35%
Loosely correlated
+6.94%
OCGN - MNPR
31%
Poorly correlated
-1.69%
IDYA - MNPR
31%
Poorly correlated
-1.75%
XNCR - MNPR
30%
Poorly correlated
-3.15%
KURA - MNPR
30%
Poorly correlated
-2.53%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with CRNX. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
-3.15%
CRNX - XNCR
60%
Loosely correlated
-0.53%
NUVL - XNCR
60%
Loosely correlated
-1.37%
IDYA - XNCR
56%
Loosely correlated
-1.75%
SYRE - XNCR
55%
Loosely correlated
-0.91%
CLDX - XNCR
55%
Loosely correlated
+2.85%
More